X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Amarin will license exclusive rights to Vazkepa (icosapent ethyl) to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Amarin
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 28, 2023
Details:
Under the terms of the agreement, CSL Seqirus will deliver an H5N8 A/Astrakhan virus vaccine candidate and will then sponsor a subsequent Phase 2 clinical trial to evaluate the candidate along with CSL Seqirus' proprietary adjuvant MF59®.
Lead Product(s): H5N8 A/Astrakhan Virus Vaccine,Squalene API
Therapeutic Area: Infections and Infectious Diseases Product Name: H5N8 A/Astrakhan
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $30.1 million Upfront Cash: Undisclosed
Deal Type: Agreement October 06, 2022
Details:
The results demonstrate that the A(H5N1) sa-mRNA influenza vaccine candidate induced an anti-HA and anti-NA neutralizing response raised by sa-mRNA influenza vaccines at a dose as low as 0.01 µg in mice and also induced HA-specific CD4+ T cells.
Lead Product(s): sa-mRNA Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Supply of AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A (H5N1) in the event of a pandemic.
Lead Product(s): Influenza A (H5N1) Monovalent Vaccine, Adjuvanted
Therapeutic Area: Infections and Infectious Diseases Product Name: Audenz
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 25, 2022
Details:
Flucelvax Quadrivalent is cell-based quadrivalent seasonal influenza vaccine (QIVc) that helps protect people aged 6 months and older from the flu.
Lead Product(s): Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Flucelvax Quadrivalent
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine, for expanded age indication for children as young as six months old. FLUCELVAX QUADRIVALENT utilizes a cell-based influenza vaccine manufacturing process.
Lead Product(s): Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Flucelvax Quadrivalent
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2021
Details:
FLUCELVAX QUADRIVALENT is a vaccine that helps protect people aged 2 and older from the flu. Vaccination with FLUCELVAX QUADRIVALENT may not protect all people who receive the vaccine.
Lead Product(s): Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Flucelvax Quadrivalent
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
QIVc and aTIV demonstrated effectiveness in preventing hospitalizations related to influenza, during both the broader influenza season and the high activity period. Flucelvax Quadrivalent is a vaccine that helps protect people aged 2 and older from the flu.
Lead Product(s): Cell-based Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Flucelvax Quadrivalent
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Under the terms of the agreements, Seqirus will have an exclusive license to commercialize tirbanibulin in Australia and New Zealand, and AVIR will have an exclusive license to commercialize tirbanibulin in Canada.
Lead Product(s): Tirbanibulin
Therapeutic Area: Dermatology Product Name: Klisyri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Athenex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2021
Details:
Under the terms of the agreements, Seqirus will have an exclusive license to commercialize tirbanibulin in Australia and New Zealand, and AVIR will have an exclusive license to commercialize tirbanibulin in Canada.
Lead Product(s): Tirbanibulin
Therapeutic Area: Dermatology Product Name: Klisyri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Athenex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
